Dongguan HEC Biopharmaceutical R&D

CompanyChina

Dongguan HEC Biopharmaceutical R&D develops one asset, in phase 2 (HEC88473 in type 2 diabetes). Mostly peptide acting on Insulin/IGF-1 signalling and GLP1R; based in China.

1
Asset
Furthest stage: Phase 2; 1
Trial: 0
Signals

Pipeline

1

HEC88473
GLP-1 receptor agonist
Phase 2, Peptide, Insulin/IGF-1 signalling, GLP1R, type 2 diabetes

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms3
Trials1
Similar companies6